Search results for "Retreatment"

showing 10 items of 79 documents

Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-[alpha]2b: A Randomized Trial

2009

BACKGROUND Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin. OBJECTIVE To evaluate use of peginterferon-alpha2a plus ribavirin to re-treat nonresponders to peginterferon-alpha2b plus ribavirin. DESIGN Randomized, parallel-group trial conducted between September 2003 and February 2007. Patients and researchers were not blinded to intervention assignment. Random assignment was centralized, computer-generated, and stratified by geographic region, hepatitis C virus (HCV) genotype, and histologic diagnosis. SETTING 106 international centers. PATIENTS 950 nonresponders to 12 or more weeks of therapy with peginterferon-alpha2b plus ribav…

Malemedicine.medical_specialtyHepatitis C virusAlpha interferonHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundDouble-Blind MethodRandomized controlled triallawPegylated interferonInternal medicineRibavirinInternal Medicineretreatment non responder hepatitis CHumansMedicineTreatment FailureNot evaluatedbusiness.industryRibavirinInterferon-alphavirus diseasesGeneral MedicineHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesSurgerychemistryRetreatmentRNA ViralDrug Therapy CombinationFemalebusinessViral loadmedicine.drug
researchProduct

Thermal Decomposition and Combustion of Microwave Pre-Treated Biomass Pellets

2021

The objective of the study was to investigate a more effective use of commercially available biomass pellets (wheat straw, wood, peat) using microwave pretreatment to improve heat production. Pellets were pretreated using the originally designed microwave torrefaction device. The effects of microwave (mw) pretreatment were quantified, providing measurements of the weight loss and elemental composition of pellets and estimating the effect of mw pretreatment on their porosity, surface area and calorific values at pretreatment temperatures of T = 448–553 K. Obtained results show that the highest structural variations and elemental composition during mw pretreatment were obtained for wheat stra…

Materials science0211 other engineering and technologiesPelletsBioengineering02 engineering and technology010501 environmental sciencesCombustionlcsh:Chemical technology01 natural scienceslcsh:ChemistryChemical Engineering (miscellaneous)lcsh:TP1-1185021108 energythermal decomposition0105 earth and related environmental sciencesheating valuewheat strawProcess Chemistry and TechnologyThermal decompositionfood and beveragesStrawTorrefactionPulp and paper industrypelletsAdiabatic flame temperaturereactivitylcsh:QD1-999peatHeat of combustionMass fractionmicrowave pretreatmentwoodcombustionProcesses
researchProduct

Autohydrolysis pretreatment of Arundo donax: a comparison between microwave-assisted batch and fast heating rate flow-through reaction systems

2015

Background: Autohydrolysis of lignocellulosic biomass in liquid hot water has been widely studied owing to its high efficiency and relatively low cost. In the perspective of industrial applications, continuous or semi-continuous processes are more interesting than batch systems. Moreover, microwave heating of pretreatment systems has been proposed to intensify the kinetics of the process. In this study, the autohydrolysis of Arundo donax was performed in pure liquid hot water using a microwave-heated batch reactor and a semi-continuous flow-through reaction system with fast heating rate at the same operating conditions with the aim of performing a systematic comparison between the two diffe…

Materials scienceMonitoringWater flowBatch reactorLignocellulosic biomassBiomassManagement Monitoring Policy and LawApplied Microbiology and BiotechnologyMass transferAutohydrolysis; Flow-through system; Lignocellulosic biomass; Liquid hot water; Microwaves; Pretreatment; Energy (all); Management Monitoring Policy and Law; Biotechnology; Applied Microbiology and Biotechnology; Renewable Energy Sustainability and the EnvironmentRenewable EnergyMicrowavesFlow-through systembiologyPolicy and LawSustainability and the EnvironmentRenewable Energy Sustainability and the Environmentbusiness.industryResearchArundo donaxLiquid hot waterSettore ING-IND/27 - Chimica Industriale E Tecnologicabiology.organism_classificationPulp and paper industryLignocellulosic biomassBiotechnologyManagementGeneral EnergyEnergy (all)AutohydrolysisScientific methodbusinessMicrowavePretreatmentBiotechnologyBiotechnology for Biofuels
researchProduct

Evaluation of the time required to perform three retreatment techniques with dental microscope and ultrasonic activation for removing filling materia…

2018

Background When endodontic treatment fails, retreatment consists of the complete removal of the root canal filling material for thorough cleaning and reobturation. Various techniques are available for the filling removal procedure, which present varying degrees of efficacy, and take a varying length of time to perform. The aim of this study was to compare the time required to carry out reciprocating, rotary, and manual techniques with dental microscope and ultrasonic activation for removing filling material from root canals. Material and Methods Ninety-nine extracted single-rooted teeth with straight and oval-shaped canals were selected. The samples were instrumented with ProTaper Gold Syst…

MicroscopeMaterials scienceRoot canal0206 medical engineeringMagnificationDentistry02 engineering and technologylaw.inventionOperative Dentistry and Endodontics03 medical and health sciencesReciprocating motion0302 clinical medicinelawmedicineGeneral DentistryEndodontic retreatmentbusiness.industryRemoval procedureResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]020601 biomedical engineeringmedicine.anatomical_structureFilling materialsUNESCO::CIENCIAS MÉDICASUltrasonic sensorbusiness
researchProduct

Characterization of lignin dissolved during alkaline pretreatment of softwood and hardwood

2015

Various alkaline pretreatments were applied to Scots pine (Pinus sylvestris) and silver/white birch (Betula pendula/pubescens) wood chips and the characterization of sulfur-free lignin dissolved was performed. The behavior of lignin during these pretreatments (alkali charge 1–8% NaOH, time 30–120 minutes, and temperature 130–150°C) was studied mainly in terms of lignin removal efficiency and molar mass distribution of dissolved lignin. The amount of lignin in pretreatment liquors increased along with an increase in the alkali charge of 0.8–4.4% and 0.6–3.4% of o.d. pine and birch wood, respectively. The most significant parameter affecting the molar mass of the dissolved lignin was shown to…

Molar massSoftwoodbiologyBetula pendula/pubescensGeneral Chemical EngineeringScots pineligninPinus sylvestrisGeneral Chemistrymolar mass distributionbiology.organism_classificationAlkali metalchemistry.chemical_compoundchemistryBetula pendulaBotanyHardwoodMolar mass distributionLigninGeneral Materials Scienceta116Alkaline pretreatmentNuclear chemistryJournal of Wood Chemistry and Technology
researchProduct

Intentional replantation for the management of maxillary sinusitis.

2007

AIM: To present a case that emphasizes the importance of the use of intentional replantation as a technique to successfully treat a periapical lesion and an odontogenic maxillary sinusitis through the alveolus at the same time. SUMMARY: This case report presents a patient with odontogenic maxillary sinusitis secondary to periapical disease of a maxillary molar that had previously received root canal treatment. The molar was extracted, with drainage and rinsing of the maxillary sinus. The apices were resected extra-orally, the retrograde cavities prepared with ultrasound and retrograde fillings of silver amalgam placed. The tooth was then replanted. After 2 years, the patient was asymptomati…

MolarAdultMaxillary sinusmedicine.medical_treatmentRetrograde ObturationRoot canalIatrogenic DiseaseDentistryengineering.materialOdontologiaTooth ReplantationmedicineHumansSinusitisGeneral DentistryOrthodonticsbusiness.industryApicoectomymedicine.diseaseMaxillary SinusitisMolarAmalgam (dentistry)medicine.anatomical_structureApicoectomyRetreatmentTooth ExtractionengineeringRetrograde ObturationFemaleTooth ReplantationbusinessPost and Core TechniqueInternational endodontic journal
researchProduct

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mant…

2017

Mantle cell lymphoma (MCL) is a rare, aggressive, incurable B-cell malignancy. Ibrutinib has been shown to be highly active for patients with relapsed/refractory (R/R) MCL. The RAY trial (MCL3001) was a phase 3, randomized, open-label, multicenter study that compared ibrutinib with temsirolimus in patients with R/R MCL. Active disease is frequently associated with impaired functional status and reduced well-being. Therefore, the current study employed two patient-reported outcome instruments, the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and the EQ-5D-5L, to assess symptoms, well-being, health status, and health-related quality of life of patients on treatment within the R…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyLymphoma Mantle-CellMalignancy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRefractoryQuality of lifePiperidinesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineDisease burdenAgedNeoplasm StagingAged 80 and overSirolimusbusiness.industryAdenineCancerHematologyMiddle Agedmedicine.diseaseTemsirolimusSurgeryPyrimidinesTreatment OutcomeOncologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisIbrutinibRetreatmentQuality of LifePyrazolesMantle cell lymphomaFemalebusinessmedicine.drug
researchProduct

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy

2016

Relationships between patient characteristics, ofatumumab pharmacokinetics, and treatment outcomes were investigated in this phase 2 trial of ofatumumab plus fludarabine and cyclophosphamide (FC) in untreated chronic lymphocytic leukemia. Patients were randomized 1:1 to receive 500 or 1000 mg ofatumumab (Cycle 1; 300 mg) plus FC every 4 weeks for six cycles. Median C(max) and C(trough) values were similar at Cycle 1 regardless of the ultimate clinical outcome. At later doses, these values were higher for patients with complete response (CR) than for other patients. Higher C(max) and C(trough) values at Cycles 3 and 6 were significantly associated with an increased likelihood of CR, whereas …

OncologyMaleCancer ResearchLymphomaDrug ResistanceMedizinKaplan-Meier EstimatePharmacologychemistry.chemical_compound0302 clinical medicineAntineoplastic Agents ImmunologicalRecurrencehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocols80 and overChronicNeoplasm MetastasisLenalidomideCancerAged 80 and overUnivariate analysisLeukemiaRemission InductionAntibodies MonoclonalHematologyphase IIMiddle AgedLymphocyticThalidomideFludarabineClinical trialTreatment OutcomeOncologyTolerability6.1 Pharmaceuticals030220 oncology & carcinogenesisRetreatmentMathematikRituximabFemalePatient SafetyRefractory Chronic Lymphocytic LeukemiaUntreated Chronic Lymphocytic Leukemiamedicine.drugAdultmedicine.medical_specialtyCyclophosphamidelenalidomideClinical Trials and Supportive ActivitiesClinical SciencesImmunologyCmaxAntineoplastic AgentsNeutropeniaOfatumumabAntibodies Monoclonal HumanizedDrug Administration ScheduleArticle03 medical and health sciencesRare DiseasesClinical ResearchChemoimmunotherapyInternal medicinemedicineImmunologic FactorsAnimalsHumansIn patientAdverse effectLenalidomideAgedNeoplasm StagingChromosome Aberrationsbusiness.industryB-CellEvaluation of treatments and therapeutic interventionsmedicine.diseaseHaresLeukemia Lymphocytic Chronic B-CellDiscontinuationClinical trialchemistryDrug Resistance NeoplasmNeoplasmbusinessCLL030215 immunology
researchProduct

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

2012

Background: Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancer patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. Patients and methods: We enrolled 39 irinotecan-refractory patients who had a clinical benefit after a line of cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same cetuximab- plus irinotecan-based therapy. Results: Median number of therapeutic li…

OncologyMaleLung NeoplasmsColorectal cancerSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntibodieCetuximab; Clinical trial; Colorectal neoplasms; Phase II; RetreatmentDrug ResistanceCetuximabadverse effects/pharmacology/therapeutic useAdult; Aged; 80 and over; Antibodies; Monoclonal; administration /&/ dosage; Antineoplastic Combined Chemotherapy Protocols; adverse effects/pharmacology/therapeutic use; Camptothecin; administration /&/ dosage/analogs /&/ derivatives; Colorectal Neoplasms; drug therapy/mortality/pathology; Disease-Free Survival; Drug Resistance; Neoplasm; Exanthema; chemically induced; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; drug therapy/mortality/secondary; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Treatment OutcomeColorectal NeoplasmKaplan-Meier EstimateAntineoplastic Combined Chemotherapy ProtocolsMonoclonal80 and overProspective cohort studyadministration /&/ dosageAged 80 and overCetuximabLiver NeoplasmsAntibodies MonoclonalHematologyMiddle AgedChemotherapy regimenPhase IIClinical trialTreatment OutcomeOncologyLiver NeoplasmLymphatic MetastasisRetreatmentchemically inducedFemaleColorectal Neoplasms/ dosage/analogs /&ampmedicine.drugHumanAdultmedicine.medical_specialtyAntibodies Monoclonal HumanizedIrinotecanAntibodiesDisease-Free SurvivalColorectal neoplasmdrug therapy/mortality/secondarySDG 3 - Good Health and Well-beingInternal medicineadministration /&/ dosage/analogs /&/ derivativesmedicine/ dosageHumansProgression-free survivalneoplasmsAgeddrug therapy/mortality/pathologyChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryLymphatic MetastasiExanthemamedicine.diseasedigestive system diseasesIrinotecanClinical trialLung Neoplasm/ derivativeDrug Resistance Neoplasmadministration /&ampNeoplasmCamptothecinbusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic …

2015

Abstract Purpose: We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective–retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183). Experimental Design: Outcomes were from the study's primary analysis. RAS mutations beyond KRAS exon 2 (KRAS exons 3, 4; NRAS exons 2, 3, 4; BRAF exon 15) were detected by bidirectional Sanger sequencing in wild-type KRAS exon 2 tumor specimens. Progression-free survival (PFS) and overall survival (OS) we…

OncologyNeuroblastoma RAS viral oncogene homologAdultMaleProto-Oncogene Proteins B-rafCancer Researchmedicine.medical_specialtyColorectal cancerPopulationDNA Mutational AnalysisLeucovorinmedicine.disease_causeInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicinePanitumumabHumansNeoplasm MetastasiseducationAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studybusiness.industryPanitumumabCancerAntibodies MonoclonalExonsMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesIrinotecanGenes rasTreatment OutcomeOncologyMutationRetreatmentFOLFIRICamptothecinFemaleKRASFluorouracilHuman medicinebusinessColorectal Neoplasmsmedicine.drugClinical cancer research
researchProduct